A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...

In a significant engineering achievement, Chennai Metro Rail Limited (CMRL) has installed India's longest precast U-girder, ...

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase ...

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025.

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...